ArticleDiagnostic and interventional radiology (Ankara, Turkey)2018
Efficacy of apparent diffusion coefficient in predicting aggressive histological features of papillary thyroid carcinoma.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Histogram-based analysis of diffusion-weighted imaging for predicting aggressiveness in papillary thyroid carcinoma.BMC medical imaging · 2022Article
- MRI-based radiomics analysis to predict preoperative lymph node metastasis in papillary thyroid carcinoma.Gland surgery · 2020Article
- First ever case report of co-occurrence of hobnail variant of papillary thyroid carcinoma and intrathyroid parathyroid adenoma in the same thyroid lobe.International journal of surgery case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to evaluate preoperative diffusion-weighted magnetic resonance imaging (DWI) for predicting aggressive histological features in papillary thyroid cancer (PTC).
methodsThis prospective study included 141 PTC patients, who underwent DWI prior to thyroidectomy; 88 patients with 88 PTC lesions were finally analyzed. Multiple comparisons of mean and minimum apparent diffusion coefficient (ADC) values (ADCmean and ADCmin) and ADC of the solid component (ADCsolid) between the lowly aggressive PTC, highly aggressive PTC without hobnail, and hobnail variant PTC groups were performed by one-way ANOVA or the Welch test. The nonparametric Kruskal-Wallis H-test was used to assess lesion size differences. Receiver-operating characteristic (ROC) curve analysis was also performed.
resultsADC values in the lowly aggressive PTC group were found to be significantly higher than those in the highly aggressive PTC without hobnail group (ADCmean: 1.35±0.20×10-3 mm2/s vs. 1.16±0.17×10-3 mm2/s, P = 0.003; ADCmin: 1.10±0.17×10-3 mm2/s vs. 0.88±0.16×10-3 mm2/s, P < 0.001; ADCsolid: 1.26±0.23×10-3 mm2/s vs. 1.04±0.17×10-3 mm2/s, P < 0.001). No significant differences for the ADCmean, ADCmin, and ADCsolid were observed between the lowly aggressive and hobnail variant PTC groups (all P > 0.05). Lesion sizes in the hobnail variant PTC group was significantly elevated compared with the lowly aggressive PTC group (2.19±1.21 cm vs. 0.93±0.37 cm, P < 0.001). Areas under the curves (AUCs) for ADCmean, ADCmin, and ADCsolid between the lowly aggressive PTC and highly aggressive PTC group without hobnail were 0.758, 0.851, and 0.787, respectively. The AUC for size between the lowly aggressive and hobnail variant PTC group was 0.896.
conclusionADCmin from DWI could potentially provide quantitative information to differentiate lowly aggressive PTC from highly aggressive PTC lesions without hobnail variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.